What is new in the treatment of steroid-induced osteoporosis?
Glucocorticoid-induced osteoporosis (GIOP) is a serious complication resulting from long-term steroid treatment. In addition to several nonpharmacologic therapies recommended by the American College of Rheumatology, various pharmacologic therapies, such as calcium, vitamin D, hormone-replacement therapy, calcitonin, and bisphosphonates, can be used to prevent and/or treat GIOP. Bisphosphonates, which are potent inhibitors of bone resorption, are considered the most effective and first-line agents for increasing bone mineral density and decreasing the risk of fracture. Human parathyroid hormone has emerged as a promising agent for the treatment of severe GIOP when used alone or in combination with a bisphosphonate.
Liu
Rosemarie H
RH
Department of Internal Medicine, Yale-New Haven Hospital, New Haven, CT, USA.
Werth
Victoria P
VP
D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D002116:Calcitonin / Q000494:pharmacology / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012968:Etidronic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D000077268:Pamidronate; D019379:Teriparatide / Q000008:administration & dosage / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D019379:Teriparatide; D002116:Calcitonin; D012968:Etidronic Acid; D000077268:Pamidronate